MedElevator
Войти в исследования Frontiers in microbiology · 2025
Clinical and radiological characteristics of Mpox pneumonia in immunosuppressed HIV-infected patients: a multicenter study from China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Wei, Zhou Zhongkai, Yuan Chunwang, Wang Fuxiang, Yin Yue, Zhao Lingling, Shi Yanbin, Chen Budong, Li Hongjun
Аннотация
BACKGROUND: In people living with HIV, particularly with low CD4+ T-cell counts, monkeypox virus (Mpox) can disseminate to visceral organs, leading to severe outcomes. Mpox pneumonia is a prominent severe phenotype, but systematic reports from China are scarce.
METHODS: This multicenter retrospective study analyzed 41 HIV-infected patients with Mpox (June 2022-February 2025), divided into a pneumonia group (n = 21) and a control group (n = 20). Clinical, laboratory, and thin-section chest computed tomography (CT) findings, multisystem involvement, outcomes, and the roles of immune status and antiretroviral therapy (ART) adherence were compared.
RESULTS: All patients were men who have sex with men. Mpox pneumonia occurred almost exclusively in patients with CD4+ T-cell counts <200/μL. Thin-section CT revealed multiple, randomly distributed, well-demarcated, non-enhancing nodules (2-36 mm), consistent with hematogenous necrotizing lesions. All pneumonia cases had ≥2 organ systems involved (e.g., proctitis, necrotic skin lesions, intestinal obstruction, sepsis). Compared with controls, pneumonia patients showed more frequent inflammation and organ injury markers (elevated C-reactive protein, procalcitonin, D-dimer, creatinine, and anemia). The case fatality rate was 38.1% (8/21) in the pneumonia group versus 0% in controls. Patients with consistent ART recovered, whereas all deaths occurred in those untreated or with irregular ART adherence.
CONCLUSION: Mpox pneumonia in HIV-infected individuals primarily affects those with advanced immunosuppression, presenting with disseminated necrotizing pulmonary nodules, multisystem involvement, and high mortality. Consistent ART markedly improves prognosis, highlighting the need for early identification of high-risk patients and integrated management-including sustained ART and targeted Mpox treatment-to reduce severe outcomes.
METHODS: This multicenter retrospective study analyzed 41 HIV-infected patients with Mpox (June 2022-February 2025), divided into a pneumonia group (n = 21) and a control group (n = 20). Clinical, laboratory, and thin-section chest computed tomography (CT) findings, multisystem involvement, outcomes, and the roles of immune status and antiretroviral therapy (ART) adherence were compared.
RESULTS: All patients were men who have sex with men. Mpox pneumonia occurred almost exclusively in patients with CD4+ T-cell counts <200/μL. Thin-section CT revealed multiple, randomly distributed, well-demarcated, non-enhancing nodules (2-36 mm), consistent with hematogenous necrotizing lesions. All pneumonia cases had ≥2 organ systems involved (e.g., proctitis, necrotic skin lesions, intestinal obstruction, sepsis). Compared with controls, pneumonia patients showed more frequent inflammation and organ injury markers (elevated C-reactive protein, procalcitonin, D-dimer, creatinine, and anemia). The case fatality rate was 38.1% (8/21) in the pneumonia group versus 0% in controls. Patients with consistent ART recovered, whereas all deaths occurred in those untreated or with irregular ART adherence.
CONCLUSION: Mpox pneumonia in HIV-infected individuals primarily affects those with advanced immunosuppression, presenting with disseminated necrotizing pulmonary nodules, multisystem involvement, and high mortality. Consistent ART markedly improves prognosis, highlighting the need for early identification of high-risk patients and integrated management-including sustained ART and targeted Mpox treatment-to reduce severe outcomes.